All In Biotech

Drug Trial Radar · NCT05392114

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

154

Actual

Start

Jul 13, 2022

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
May 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).

Conditions

  • Hereditary Angioedema

Interventions

  • DonidalorsenDrug

    Donidalorsen will be administered by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by SeverityTime frame: Up to approximately 70 weeks, plus 104 weeks for Group 1; up to approximately 76 weeks, plus 104 weeks for Group 2

Locations

50 sites in 14 countries. Site status is shown where the registry gives one.

  • Ionis Investigative Site

    Paradise Valley, Arizona

  • Ionis Investigative Site

    La Jolla, California

  • Ionis Investigative Site

    Santa Monica, California

  • Ionis Investigative Site

    Walnut Creek, California

  • Ionis Investigative Site

    Tampa, Florida

  • Ionis Investigative Site

    Kansas City, Kansas

  • Ionis Investigative Site

    Boston, Massachusetts

  • Ionis Investigative Site

    Ann Arbor, Michigan

  • Ionis Investigative Site

    Detroit, Michigan

  • Ionis Investigative Site

    St Louis, Missouri

  • Ionis Investigative Site

    Mooresville, North Carolina

  • Ionis Investigative Site

    Cincinnati, Ohio

  • Ionis Investigative Site

    Columbus, Ohio

  • Ionis Investigative Site

    Hershey, Pennsylvania

  • Ionis Investigative Site

    Dallas, Texas

  • Ionis Investigative Site

    Murray, Utah

  • Ionis Investigative Site

    Edegem, Belgium

  • Ionis Investigative Site

    Sofia, Bulgaria

  • Ionis Investigative Site

    Sofia, Bulgaria

  • Ionis Investigative Site

    Edmonton, Canada

  • Ionis Investigative Site

    Ottawa, Ontario, Canada

  • Ionis Investigative Site

    La Tronche, France

  • Ionis Investigative Site

    Marseille, France

  • Ionis Investigative Site

    Paris, France

  • Ionis Investigative Site

    Berlin, Germany

  • Ionis Investigative Site

    Frankfurt, Germany

  • Ionis Investigative Site

    München, Germany

  • Ionis Investigative Site

    Ashkelon, Israel

  • Ionis Investigative Site

    Haifa, Israel

  • Ionis Investigative Site

    Tel Aviv, Israel

  • Ionis Investigative Site

    Catania, Italy

  • Ionis Investigative Site

    Naples, Italy

  • Ionis Investigative Site

    Padova, Italy

  • Ionis Investigative Site

    Palermo, Italy

  • Ionis Investigative Site

    San Donato Milanese, Italy

  • Ionis Investigative Site

    Amsterdam, Netherlands

  • Ionis Investigative Site

    Groningen, Netherlands

  • Ionis Investigative Site

    Krakow, Poland

  • Ionis Investigative Site

    San Juan, Puerto Rico

  • Ionis Investigative Site

    Barcelona, Spain

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.